These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 35995127)

  • 1. Partial MCT1 invalidation protects against diet-induced non-alcoholic fatty liver disease and the associated brain dysfunction.
    Hadjihambi A; Konstantinou C; Klohs J; Monsorno K; Le Guennec A; Donnelly C; Cox IJ; Kusumbe A; Hosford PS; Soffientini U; Lecca S; Mameli M; Jalan R; Paolicelli RC; Pellerin L
    J Hepatol; 2023 Jan; 78(1):180-190. PubMed ID: 35995127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of VEGF-B signaling prevents non-alcoholic fatty liver disease development by targeting lipolysis in the white adipose tissue.
    Falkevall A; Mehlem A; Folestad E; Ning FC; Osorio-Conles Ó; Radmann R; de Hollanda A; Wright SD; Scotney P; Nash A; Eriksson U
    J Hepatol; 2023 May; 78(5):901-913. PubMed ID: 36717026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delayed intervention with a novel SGLT2 inhibitor NGI001 suppresses diet-induced metabolic dysfunction and non-alcoholic fatty liver disease in mice.
    Chiang H; Lee JC; Huang HC; Huang H; Liu HK; Huang C
    Br J Pharmacol; 2020 Jan; 177(2):239-253. PubMed ID: 31497874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Macrophage scavenger receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease.
    Govaere O; Petersen SK; Martinez-Lopez N; Wouters J; Van Haele M; Mancina RM; Jamialahmadi O; Bilkei-Gorzo O; Lassen PB; Darlay R; Peltier J; Palmer JM; Younes R; Tiniakos D; Aithal GP; Allison M; Vacca M; Göransson M; Berlinguer-Palmini R; Clark JE; Drinnan MJ; Yki-Järvinen H; Dufour JF; Ekstedt M; Francque S; Petta S; Bugianesi E; Schattenberg JM; Day CP; Cordell HJ; Topal B; Clément K; Romeo S; Ratziu V; Roskams T; Daly AK; Anstee QM; Trost M; Härtlova A
    J Hepatol; 2022 May; 76(5):1001-1012. PubMed ID: 34942286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. APOC3 Protein Is Not a Predisposing Factor for Fat-induced Nonalcoholic Fatty Liver Disease in Mice.
    Cheng X; Yamauchi J; Lee S; Zhang T; Gong Z; Muzumdar R; Qu S; Dong HH
    J Biol Chem; 2017 Mar; 292(9):3692-3705. PubMed ID: 28115523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistance to diet-induced obesity and associated metabolic perturbations in haploinsufficient monocarboxylate transporter 1 mice.
    Lengacher S; Nehiri-Sitayeb T; Steiner N; Carneiro L; Favrod C; Preitner F; Thorens B; Stehle JC; Dix L; Pralong F; Magistretti PJ; Pellerin L
    PLoS One; 2013; 8(12):e82505. PubMed ID: 24367518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Voluntary exercise in mice fed an obesogenic diet alters the hepatic immune phenotype and improves metabolic parameters - an animal model of life style intervention in NAFLD.
    Gehrke N; Biedenbach J; Huber Y; Straub BK; Galle PR; Simon P; Schattenberg JM
    Sci Rep; 2019 Mar; 9(1):4007. PubMed ID: 30850619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver sympathetic denervation reverses obesity-induced hepatic steatosis.
    Hurr C; Simonyan H; Morgan DA; Rahmouni K; Young CN
    J Physiol; 2019 Sep; 597(17):4565-4580. PubMed ID: 31278754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Western diet-induced mouse model of non-alcoholic fatty liver disease associated with metabolic outcomes: Features of gut microbiome-liver-adipose tissue axis.
    Romualdo GR; Valente LC; Sprocatti AC; Bacil GP; de Souza IP; Rodrigues J; Rodrigues MAM; Vinken M; Cogliati B; Barbisan LF
    Nutrition; 2022; 103-104():111836. PubMed ID: 36202025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An in vitro and in vivo study of a 4-herb formula on the management of diet-induced metabolic syndrome.
    Wat E; Wang Y; Chan K; Law HW; Koon CM; Lau KM; Leung PC; Yan C; Lau CBS
    Phytomedicine; 2018 Mar; 42():112-125. PubMed ID: 29655677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Diet Induced Maladaptive Increase in Hepatic Mitochondrial DNA Precedes OXPHOS Defects and May Contribute to Non-Alcoholic Fatty Liver Disease.
    Malik AN; Simões ICM; Rosa HS; Khan S; Karkucinska-Wieckowska A; Wieckowski MR
    Cells; 2019 Oct; 8(10):. PubMed ID: 31597406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatic metabolic adaptation and adipose tissue expansion are altered in mice with steatohepatitis induced by high-fat high sucrose diet.
    Baiges-Gaya G; Fernández-Arroyo S; Luciano-Mateo F; Cabré N; Rodríguez-Tomàs E; Hernández-Aguilera A; Castañé H; Romeu M; Nogués MR; Camps J; Joven J
    J Nutr Biochem; 2021 Mar; 89():108559. PubMed ID: 33264665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Associations of altered hepatic gene expression in American lifestyle-induced obesity syndrome diet-fed mice with metabolic changes during NAFLD development and progression.
    Iannone V; Lok J; Babu AF; Gómez-Gallego C; Willman RM; Koistinen VM; Klåvus A; Kettunen MI; Kårlund A; Schwab U; Hanhineva K; Kolehmainen M; El-Nezami H
    J Nutr Biochem; 2023 May; 115():109307. PubMed ID: 36868506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIF-P4H-2 inhibition enhances intestinal fructose metabolism and induces thermogenesis protecting against NAFLD.
    Laitakari A; Tapio J; Mäkelä KA; Herzig KH; Dengler F; Gylling H; Walkinshaw G; Myllyharju J; Dimova EY; Serpi R; Koivunen P
    J Mol Med (Berl); 2020 May; 98(5):719-731. PubMed ID: 32296880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monocarboxylate transporter 1 in the liver modulates high-fat diet-induced obesity and hepatic steatosis in mice.
    Luo X; Li Z; Chen L; Zhang X; Zhu X; Wang Z; Chen Y
    Metabolism; 2023 Jun; 143():155537. PubMed ID: 36933792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The FATZO mouse, a next generation model of type 2 diabetes, develops NAFLD and NASH when fed a Western diet supplemented with fructose.
    Sun G; Jackson CV; Zimmerman K; Zhang LK; Finnearty CM; Sandusky GE; Zhang G; Peterson RG; Wang YJ
    BMC Gastroenterol; 2019 Mar; 19(1):41. PubMed ID: 30885145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Susceptibility of Different Mouse Wild Type Strains to Develop Diet-Induced NAFLD/AFLD-Associated Liver Disease.
    Fengler VH; Macheiner T; Kessler SM; Czepukojc B; Gemperlein K; Müller R; Kiemer AK; Magnes C; Haybaeck J; Lackner C; Sargsyan K
    PLoS One; 2016; 11(5):e0155163. PubMed ID: 27167736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human germline hedgehog pathway mutations predispose to fatty liver.
    Guillen-Sacoto MJ; Martinez AF; Abe Y; Kruszka P; Weiss K; Everson JL; Bataller R; Kleiner DE; Ward JM; Sulik KK; Lipinski RJ; Solomon BD; Muenke M
    J Hepatol; 2017 Oct; 67(4):809-817. PubMed ID: 28645738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation.
    Porras D; Nistal E; Martínez-Flórez S; Pisonero-Vaquero S; Olcoz JL; Jover R; González-Gallego J; García-Mediavilla MV; Sánchez-Campos S
    Free Radic Biol Med; 2017 Jan; 102():188-202. PubMed ID: 27890642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nrg4 promotes fuel oxidation and a healthy adipokine profile to ameliorate diet-induced metabolic disorders.
    Chen Z; Wang GX; Ma SL; Jung DY; Ha H; Altamimi T; Zhao XY; Guo L; Zhang P; Hu CR; Cheng JX; Lopaschuk GD; Kim JK; Lin JD
    Mol Metab; 2017 Aug; 6(8):863-872. PubMed ID: 28752050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.